American Pharmacists Association (APhA)
Trade associationSupport
Drug repurposing priority areas
Drug Repurposing for Unmet Medical Needs; Request for Information
FDA-2026-N-4492-0001RFI
Comments
608
Last activity Jul 13, 2026
Deadline
Closed on Jul 14, 2026
Closed Jul 14, 2026
Net supportiSupport minus oppose · campaigns included
+95%
+95% excluding campaigns
Document
Details
The document's own metadata, straight from the source system.
- Title
- Drug Repurposing for Unmet Medical Needs; Request for Information
- Posted
- May 12, 2026
- Comment period
- May 12, 2026 – Jul 14, 2026
- FR Doc
- 2026-09366
Analysis
Overview
What the public is saying — stance, who's commenting, and the issues they raise.
Include campaigns
Stance breakdown
+95%
Net support
Support578Oppose2Other28
Aggregates include form-letter campaigns. Excluding them, net support is +95% across organic comments.
Who commented
Breakdown by commenter type.
Academic
20
Business
56
Individual
425
Trade association
8
Advocacy
59
Other
40
Comments over time
Weekly arrivals, stacked by stance.
Posted May 12, 2026Deadline Jul 14, 2026
May 11May 25Jun 8Jun 22Jul 6Jul 13
Support578Oppose2Other28
Support × commenter type
How each type splits across stance.
Support
Oppose
Other
Individual
93%
0%
6%
Advocacy
100%
0%
0%
Business
100%
0%
0%
Other
95%
0%
5%
Academic
100%
0%
0%
Trade association
100%
0%
0%
Issues raised
The docket's canonical issues. Select one to browse its comments.
Drug repurposing for long covid82
Expand fda-approved indications65
Treatment for long covid64
Economic barriers to drug repurposing54
Incentives for drug repurposing43
Commercial and incentive barriers36
Ketamine for mental health33
Ketamine treatment efficacy29
Expanded clinical indications28
Patient access and affordability28
Position map
Who stands where on each issue?
Every non-silent position is backed by an excerpt from the comment.
Issues shown
Uncheck an issue to choose another.
| Organization | Economic barriers to drug repurposing | Incentives for drug repurposing | Ai-driven drug repurposing technology | Commercial and incentive barriers | Drug repurposing priority areas |
|---|---|---|---|---|---|
American Pharmacists Association (APhA) Trade associationSupport The American Pharmacists Association (APhA) supports the FDA's drug repurposing efforts to accelerate patient access to | · | · | · | · | |
American Society of Transplant Surgeons Trade associationSupport The American Society of Transplant Surgeons (ASTS) supports the FDA's interest in drug repurposing to expand access to i | · | · | · | · | · |
AmoSey Inc. BusinessSupport AmoSey Inc., a Canadian life sciences advisory firm, supports the FDA's initiative on drug repurposing and provides spec | · | · | · | ||
Aspartes Pharmaceuticals, Inc. BusinessSupport Aspartes Pharmaceuticals, Inc. | · | · | · | · | |
AUTM Trade associationSupport AUTM, representing a group of university technology transfer offices and industry developers, supports the FDA's request | · | · | · | ||
Biostax Corp d/b/a Attune Biotech Inc. BusinessSupport Biostax Corp (Attune Biotech Inc.) submits a white paper supporting the FDA's initiative to modernize drug repurposing f | · | · | · | · | · |
Diagnostic Green LLC BusinessSupport Diagnostic Green LLC, representing Renew Pharmaceuticals Ltd., supports the FDA's initiative to solicit input on drug re | · | · | · | · | |
Main Street Foundation AdvocacySupport The Main Street Foundation's Center for Regulatory Analysis and Engagement (CRAE) supports the FDA's efforts to identify | · | · | · | · | · |
Muscular Dystrophy Association AdvocacySupport The Muscular Dystrophy Association (MDA) supports the FDA's initiative on drug repurposing, specifically advocating for | · | · | · | · | |
National Leiomyosarcoma Foundation AdvocacySupport The National Leiomyosarcoma Foundation (NLMSF) supports the FDA's initiative to explore drug repurposing for diseases wi | · | · | · | · | |
Nexus Concordat BusinessSupport Marjorie McCubbins, Founder of Nexus Concordat, submits a comment supporting the FDA's Request for Information on drug r | · | · | · | · | |
NuSirt Sciences, Inc. BusinessSupport Michael B. | · | · | · | · | · |
Pfizer Inc BusinessSupport Pfizer Inc. | · | · | · | · | |
Research!America AdvocacySupport Research!America, a nonprofit alliance, supports the FDA's Request for Information on drug repurposing for unmet medical | · | · | · | · | |
Sen-Jam Pharmaceutical BusinessSupport Sen-Jam Pharmaceutical supports the FDA's drug repurposing RFI but recommends expanding the scope to include a mechanist | · | · | · | · | |
Single Dose Therapeutics, Inc. BusinessSupport Single Dose Therapeutics, Inc., an early-stage biotechnology company, supports the FDA's interest in drug repurposing to | · | · | · | ||
The RWE Alliance Trade associationSupport The RWE Alliance, a coalition of real-world data and analytics organizations, supports the FDA's efforts to identify dru | · | · | · | · |
American Society of Transplant Surgeons
Trade associationSupport
AmoSey Inc.
BusinessSupport
Economic barriers to drug repurposing
Incentives for drug repurposing
Aspartes Pharmaceuticals, Inc.
BusinessSupport
Incentives for drug repurposing
AUTM
Trade associationSupport
Incentives for drug repurposing
Commercial and incentive barriers
Biostax Corp d/b/a Attune Biotech Inc.
BusinessSupport
Diagnostic Green LLC
BusinessSupport
Commercial and incentive barriers
Main Street Foundation
AdvocacySupport
Muscular Dystrophy Association
AdvocacySupport
Economic barriers to drug repurposing
National Leiomyosarcoma Foundation
AdvocacySupport
Drug repurposing priority areas
Nexus Concordat
BusinessSupport
Ai-driven drug repurposing technology
NuSirt Sciences, Inc.
BusinessSupport
Pfizer Inc
BusinessSupport
Economic barriers to drug repurposing
Research!America
AdvocacySupport
Economic barriers to drug repurposing
Sen-Jam Pharmaceutical
BusinessSupport
Economic barriers to drug repurposing
Single Dose Therapeutics, Inc.
BusinessSupport
Economic barriers to drug repurposing
Incentives for drug repurposing
The RWE Alliance
Trade associationSupport
Ai-driven drug repurposing technology
21 organization-typed comments could not be identified.
Comments
Explorer
Every mirrored comment — filter by stance, campaign, or issue.
Filter:
- Jul 13, 2026Comment from AnonymousSupportIndividual📎 Attachment
A medical doctor provides information on the potential for repurposing anti-CD38 drugs, specifically daratumumab and isatuximab, to treat ME/CFS and Long Covid. The commenter highlights successful pilot study results and argues that these drugs are exciting prospects for repurposing due to their efficacy in other conditions and the high prevalence of these chronic diseases.
Read comment → - Jul 13, 2026Comment from Martha YoungSupportIndividual
An individual is urging the agency to support drug repurposing specifically for the treatment of Long Covid. They argue that the large number of affected people and the lack of currently approved treatments make it an ideal candidate for repurposing.
Read comment → - Jul 13, 2026Comment from AnonymousSupportIndividual
An individual consumer with Long Covid and a primary immunodeficiency advocates for the FDA to approve Pemgarda as a treatment for Long Covid. The commenter shares their personal experience with the drug's efficacy and urges the FDA to provide full approval and create financial incentives for further research into monoclonal antibody treatments.
Read comment → - Jul 13, 2026Comment from AnonymousSupportIndividual
An individual is sharing a personal anecdote regarding the positive effects of the drug PEMGARDA on a loved one's long COVID symptoms. They are requesting that the FDA consider approving PEMGARDA for general use and as a treatment for long COVID.
Read comment → - Jul 11, 2026Comment from Lisa PellegrinoSupportIndividual
The commenter supports the prioritization of off-label use of existing medications to treat long Covid. They argue that the lack of FDA-approved treatments is hampering healthcare providers and that clinical evidence should be used to address the millions of people suffering from the condition.
Read comment → - Jul 10, 2026Comment from Biostax Corp d/b/a Attune Biotech Inc.SupportBusiness📎 Attachment
Biostax Corp (Attune Biotech Inc.) submits a white paper supporting the FDA's initiative to modernize drug repurposing for unmet medical needs. They argue that low-dose naltrexone (LDN) is a prime candidate for this framework because it has established safety, widespread clinical use, and significant federal research support, but lacks a standardized, FDA-approved pharmaceutical product due to market failures.
Read comment → - Jun 29, 2026Comment from Gillian McCreaSupportOther
The commenter advocates for the FDA to consider repurposing the approved drug Mitapivat (Pyrukynd) for the treatment of Long COVID. They argue that the drug's ability to increase ATP production directly addresses the energy metabolism deficits and mitochondrial dysfunction observed in patients with Long COVID and ME/CFS.
Read comment → - Jun 29, 2026Comment from Gillian McCreaSupportOther
The Mitochondrial Transplantation Institute (Mitoclinics) is advocating for the FDA to oversee a clinical trial for autologous mitochondrial transplantation to treat the energy deficit in Long COVID. They argue that the procedure has a proven human precedent in pediatric cardiac care and a clear mechanistic match for the fatigue associated with Long COVID.
Read comment → - Jun 29, 2026Comment from Gillian McCreaSupportBusiness
StemCyte is advocating for the accelerated approval and repurposing of its cord blood cell therapy, REGENECYTE, for the treatment of Long COVID fatigue. They highlight positive Phase IIa trial data and request that the FDA address cost and coverage barriers to ensure patient access.
Read comment → - Jun 29, 2026Comment from Gillian McCreaSupportIndividual
The commenter advocates for the FDA to consider repurposing the drug Tezepelumab (Tezspire) for the treatment of Long COVID. They argue that because Tezepelumab blocks the upstream alarmin TSLP, it could effectively address the mast cell and type-2 inflammation associated with various Long COVID symptoms.
Read comment →